During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy. Here's a look at the most recent high-yield dividend stock ratings from the most accurate Wall Street analysts, according to Benzinga's Analyst Stock Ratings.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the energy sector.
Antero Midstream Corporation AM
- Dividend Yield: 7.41%
- Goldman Sachs analyst John Mackay reinstated a Neutral rating with a price target of $12.5 on Oct. 6, 2023. This analyst has an accuracy rate of 74%.
- JP Morgan analyst Jeremy Tonet maintained an Underweight rating and cut the price target from $12 to $11 on July 21, 2023. This analyst has an accuracy rate of 61%.
- Recent News: Antero Midstream posted better-than-expected second-quarter earnings.
Kinder Morgan, Inc. KMI
- Dividend Yield: 6.74%
- Goldman Sachs analyst John Mackay reinstated a Buy rating with a price target of $20 on Oct. 6, 2023. This analyst has an accuracy rate of 74%.
- Stifel analyst Selman Akyol maintained a Hold rating and raised the price target from $21 to $22 on Aug. 1, 2023. This analyst has an accuracy rate of 66%.
- Recent News: Kinder Morgan posted weaker-than-expected second-quarter sales.
Equitrans Midstream Corporation ETRN
- Dividend Yield: 6.23%
- Goldman Sachs analyst John Mackay reinstated a Buy rating with a price target of $11.5 on Oct. 6, 2023. on July 28, 2023. This analyst has an accuracy rate of 74%.
- RBC Capital analyst TJ Schultz reiterated an Outperform rating with a price target of $13 on Aug. 8, 2023. This analyst has an accuracy rate of 65%.
- Recent News: Equitrans Midstream posted better-than-expected second-quarter earnings.
Read More: Cadrenal Therapeutics And 3 Other Stocks Under $3 Insiders Are Buying
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.